|
WO1982001011A1
(en)
|
1980-09-24 |
1982-04-01 |
Corp Cetus |
Diagnostic method and probe
|
|
EP0084796B1
(en)
|
1982-01-22 |
1990-05-02 |
Cetus Corporation |
Hla typing method and cdna probes used therein
|
|
US4582788A
(en)
|
1982-01-22 |
1986-04-15 |
Cetus Corporation |
HLA typing method and cDNA probes used therein
|
|
US4683194A
(en)
|
1984-05-29 |
1987-07-28 |
Cetus Corporation |
Method for detection of polymorphic restriction sites and nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
CA1284931C
(en)
|
1986-03-13 |
1991-06-18 |
Henry A. Erlich |
Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
|
|
CA1338457C
(en)
|
1986-08-22 |
1996-07-16 |
Henry A. Erlich |
Purified thermostable enzyme
|
|
US5093330A
(en)
|
1987-06-15 |
1992-03-03 |
Ciba-Geigy Corporation |
Staurosporine derivatives substituted at methylamino nitrogen
|
|
US6605712B1
(en)
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
WO2003070887A2
(en)
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2206517B1
(en)
|
2002-07-03 |
2023-08-02 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions comprising anti-PD-L1 antibodies
|
|
NZ595313A
(en)
|
2005-02-18 |
2013-03-28 |
Abraxis Bioscience Llc |
The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
EP1951729B1
(en)
*
|
2005-11-16 |
2014-06-25 |
Cell Therapeutics, Inc. |
Oxygen linked pyrimidine derivatives
|
|
CA2682356C
(en)
|
2007-04-16 |
2016-06-14 |
Abbott Laboratories |
7-substituted indole mcl-1 inhibitors
|
|
JP5191537B2
(ja)
|
2007-06-18 |
2013-05-08 |
エム・エス・ディー・オス・ベー・フェー |
ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
|
|
GB0806652D0
(en)
|
2008-04-11 |
2008-05-14 |
Glaxo Group Ltd |
Anhydrous crystal form of orvepitant maleate
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
RS54233B1
(sr)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
Kompozicije pd-1 antagonista i postupci za njihovu primenu
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
US20120148661A1
(en)
|
2009-04-15 |
2012-06-14 |
Poniard Pharmaceuticals, Inc. |
High bioavailability oral picoplatin anti-cancer therapy
|
|
JP4965623B2
(ja)
|
2009-09-30 |
2012-07-04 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
|
|
ES2632548T3
(es)
*
|
2010-02-05 |
2017-09-14 |
Tragara Pharmaceuticals, Inc. |
Formas de estado sólido de los inhibidores de la quinasa macrocíclica
|
|
WO2011103016A2
(en)
|
2010-02-19 |
2011-08-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inhibiting ezh2
|
|
WO2011127202A2
(en)
|
2010-04-06 |
2011-10-13 |
Fred Hutchinson Cancer Research Center |
Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
|
BR112013005806B1
(pt)
|
2010-09-10 |
2022-05-10 |
Epizyme, Inc |
Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
CA2850570A1
(en)
|
2011-09-30 |
2013-04-04 |
Glaxosmithkline Llc |
Methods of treating cancer
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
KR102587175B1
(ko)
|
2012-03-12 |
2023-10-06 |
에피자임, 인코포레이티드 |
인간 ｅｚｈ2의 억제제 및 이의 사용 방법
|
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
WO2014022332A1
(en)
|
2012-07-31 |
2014-02-06 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
CA2887243C
(en)
|
2012-10-15 |
2024-04-09 |
Epizyme, Inc. |
Methods of treating cancer
|
|
PL2958916T3
(pl)
|
2013-02-21 |
2019-01-31 |
Pfizer Inc. |
Stałe postacie selektywnego inhibitora CDK4/6
|
|
HRP20201113T1
(hr)
|
2013-03-15 |
2020-10-30 |
Glaxosmithkline Intellectual Property Development Limited |
Vežući proteini protiv lag-3
|
|
PL3043816T3
(pl)
|
2013-09-11 |
2020-03-31 |
Medimmune Limited |
Przeciwciała anty-b7-h1 do leczenia nowotworów
|
|
JP6538707B2
(ja)
|
2014-03-07 |
2019-07-03 |
ユニバーシティ ヘルス ネットワーク |
免疫応答を調節するための方法及び組成物
|
|
PH12021551647A1
(en)
|
2014-03-14 |
2022-06-06 |
Agios Pharmaceuticals Inc |
Pharmaceutical compositions of therapeutically active compounds
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
ES2941687T3
(es)
|
2016-03-24 |
2023-05-24 |
Cothera Bioscience Inc |
Tratamiento del cáncer con TG02
|
|
KR102758037B1
(ko)
|
2017-08-18 |
2025-01-22 |
코테라 바이오사이언스 인코포레이티드 |
Tg02의 다형성 형태
|